GRP
MTNB icon

Global Retirement Partners’s Matinas BioPharma MTNB Stock Holding History

Global Retirement Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$18K – 3313
2023
Q2 		$18K Sell
1,000
-1,000
-50% -$23.3K ﹤0.01% 1711
2023
Q1 		$59.1K Sell
2,000
-780
-28% -$19.7K ﹤0.01% 1166
2022
Q4 		$69.5K Buy
+2,780
New +$92.5K ﹤0.01% 953

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Global Retirement Partners's MTNB Position: Q3 2023 in Review

Global Retirement Partners sold out of Matinas BioPharma (MTNB) in Q3 2023, closing a stake of 1,000 shares — an estimated $18K sold.

Global Retirement Partners first reported a position in MTNB in Q4 2022 and held it in 3 quarters. The position peaked at $69.5K in Q4 2022. 47 funds tracked by Wall St. Rank hold MTNB as of Q3 2023.

  • Global Retirement Partners reported no remaining Matinas BioPharma position as of Q3 2023 after selling out during the quarter.
  • Global Retirement Partners sold 1,000 Matinas BioPharma shares in Q3 2023, an estimated $18K.
  • Global Retirement Partners first reported a position in Matinas BioPharma in Q4 2022 and held it in 3 quarters.
  • Global Retirement Partners's Matinas BioPharma position peaked at $69.5K in Q4 2022.
  • 47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2023.

Based on Global Retirement Partners's 13F filing for Q3 2023, filed 13 Oct 2023.